Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × NIH × Dermatologic × Clear all

Phase

Phase 2 167 Phase 1 111 Phase 1/2 41 Phase 3 23 Phase NA 9 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 14 INDUSTRY 11 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Thoracic 5 Lymphoid 5 Gastrointestinal 5 Sarcoma 4 Head & Neck 4 Gynecologic 4 Genitourinary 4 Myeloid 3 Classical hematology 2 CNS 2 Plasma cell 1 Endocrine 1 Dermatologic 1

Conditions

Interventions

sargramostim 1 Specimen Handling 1 Nivolumab 1 Ipilimumab 1 Colony-Stimulating Factors 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02339571 2026-03-19

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡